Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Agency initiates safety label change and notifies physicians of possible link
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Subscribe To Our Newsletter & Stay Updated
